Kimberly Staffey, MD
Cardiovascular Disease · Iowa City, IANPI 1184634099
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,000 of the $6,528 with a category attached, or 76.6%. Boston Scientific accounts for 81.3% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $5,262, more than ten times the $184 reported in 2019.
Across 30 payments — averaging $217.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Abbott$970
- Philips North America LLC$184
- Shockwave Medical, Inc$42
- Impulse Dynamics (USA) Inc.$25
What the payments were for
- Speaking & faculty fees$5,00077%
- Travel & lodging$85713%
- Food & beverage$67110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $5,307 |
| Abbott | 9 | $970 |
| Philips North America LLC | 1 | $184 |
| Shockwave Medical, Inc | 2 | $42 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$5,000
- Azurion 7 M20$184
How this compares
$6,528 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $38,655 |
| Atorvastatin Calcium | 73 | $627 |
| Metoprolol Succinate | 63 | $430 |
| Potassium Chloride | 35 | $359 |
| Rosuvastatin Calcium | 30 | $314 |
| Losartan Potassium | 26 | $221 |
| Furosemide | 42 | $212 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $176 |
| Nitroglycerin | 13 | $142 |
| Amlodipine Besylate | 25 | $126 |
| Ezetimibe | 12 | $93 |
| Lisinopril | 26 | $86 |
| ClopidogrelClopidogrel Bisulfate | 11 | $38 |
| Metoprolol Tartrate | 15 | $36 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Iowa City
- Brian OlshanskyIowa City$219K
- Jennifer RobinsonIowa City$37K
- Aaron SifuentesIowa City$5K
- Suvasini LakshmananIowa City$4K
- Rakesh PonnapureddyIowa City$3K
- Corina IorgoveanuIowa City$2K
- Michael HajduIowa City$2K
- Boniface MalanguIowa City$2K
- Ferhaan AhmadIowa City$2K
- Brett JohnsonIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.